Soleus Capital Management, L.P.: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1802630) · Explore on the interactive board
Soleus Capital Management, L.P. disclosed 97 US equity positions worth $2.9bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 11, 2026). Its largest position is KRYS at 12.0% of the reported book, followed by CELC, TGTX. The top ten holdings are 48.9% of the book, and the portfolio behaves like about 27 equal-weight positions. Versus the prior filing it opened 22 new positions, added to 25, reduced 41 and exited 18. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Soleus Capital Management, L.P. own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 22 new, 25 added, 41 reduced, 18 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | KRYS KRYSTAL BIOTECH INC | Healthcare | 12.0% | $349.1m | 939,254 | -19% | reduced |
| 2 | CELC CELCUITY INC | Healthcare | 6.1% | $178.3m | 1,704,318 | 33% | added |
| 3 | TGTX TG THERAPEUTICS INC | Healthcare | 5.5% | $160.9m | 2,927,895 | -27% | reduced |
| 4 | PODD INSULET CORP | Healthcare | 5.5% | $159.7m | 1,049,000 | 86% | added |
| 5 | NVCR NOVOCURE LTD | Healthcare | 5.2% | $150.2m | 9,913,401 | -6% | reduced |
| 6 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 4.2% | $122.2m | 225,587 | 21% | added |
| 7 | INSP INSPIRE MED SYS INC | Healthcare | 3.0% | $86.2m | 1,931,436 | 235% | added |
| 8 | RIGL RIGEL PHARMACEUTICALS INC | 2.5% | $72.1m | 1,843,504 | 18335% | added | |
| 9 | ANIP ANI PHARMACEUTICALS INC | Healthcare | 2.5% | $71.8m | 867,760 | 6% | added |
| 10 | BBNX BETA BIONICS INC | Healthcare | 2.4% | $68.8m | 4,393,714 | 1% | added |
| 11 | VCEL VERICEL CORP | Healthcare | 2.2% | $64.9m | 1,459,152 | -43% | reduced |
| 12 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 2.0% | $59.4m | 177,517 | -46% | reduced |
| 13 | GERN GERON CORP | Healthcare | 1.9% | $54.8m | 42,808,659 | 3% | added |
| 14 | ALKS ALKERMES PLC | Healthcare | 1.9% | $53.9m | 1,029,252 | -48% | reduced |
| 15 | ERAS ERASCA INC | Healthcare | 1.7% | $49.5m | 2,700,000 | – | new |
| 16 | NPCE NEUROPACE INC | 1.6% | $46.3m | 2,911,122 | -1% | reduced | |
| 17 | PGNY PROGYNY INC | Healthcare | 1.6% | $46.2m | 1,602,000 | -22% | reduced |
| 18 | INDV INDIVIOR PHARMACEUTICALS INC | Healthcare | 1.5% | $43.7m | 1,064,000 | -16% | reduced |
| 19 | PARABILIS MEDICINES INC | 1.4% | $40.1m | 1,465,070 | – | new | |
| 20 | EDAP TMS S A | 1.3% | $37.9m | 7,309,254 | 0% | held | |
| 21 | GMED GLOBUS MED INC | Healthcare | 1.3% | $37.0m | 468,922 | -36% | reduced |
| 22 | RCUS ARCUS BIOSCIENCES INC | Healthcare | 1.2% | $36.0m | 1,168,738 | 159% | added |
| 23 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.2% | $35.6m | 1,628,039 | -6% | reduced |
| 24 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.2% | $35.5m | 1,465,163 | 56% | added |
| 25 | LEGN LEGEND BIOTECH CORP | Healthcare | 1.2% | $34.8m | 1,205,000 | – | new |
| 26 | JBIO JADE BIOSCIENCES INC | Healthcare | 1.2% | $34.5m | 1,550,690 | 95% | added |
| 27 | UNH UNITEDHEALTH GROUP INC | Healthcare | 1.1% | $33.3m | 80,000 | – | new |
| 28 | AVTX AVALO THERAPEUTICS INC | Healthcare | 1.1% | $30.6m | 1,654,978 | 274% | added |
| 29 | URGN UROGEN PHARMA LTD | Healthcare | 1.1% | $30.5m | 829,810 | 14% | added |
| 30 | MBX MBX BIOSCIENCES INC | Healthcare | 1.0% | $28.4m | 515,279 | 188% | added |
| 31 | PALI PALISADE BIO INC | Healthcare | 0.9% | $27.3m | 13,063,687 | – | new |
| 32 | PHVS PHARVARIS N V | Healthcare | 0.9% | $25.3m | 730,907 | 4% | added |
| 33 | ORGO ORGANOGENESIS HLDGS INC | Healthcare | 0.8% | $24.6m | 10,140,951 | 1% | added |
| 34 | SUPN SUPERNUS PHARMACEUTICALS | Healthcare | 0.8% | $24.2m | 520,000 | – | new |
| 35 | PRCT PROCEPT BIOROBOTICS CORP | Healthcare | 0.8% | $22.6m | 1,003,000 | 527% | added |
| 36 | TNGX TANGO THERAPEUTICS INC | Healthcare | 0.8% | $22.2m | 709,000 | 58% | added |
| 37 | IKT INHIBIKASE THERAPEUTICS INC | 0.8% | $22.1m | 10,875,000 | 0% | held | |
| 38 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.8% | $22.0m | 1,179,618 | -27% | reduced |
| 39 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 0.7% | $21.5m | 375,572 | -42% | reduced |
| 40 | LIVN LIVANOVA PLC | Healthcare | 0.7% | $21.0m | 254,957 | -56% | reduced |
| 41 | ARGX ARGENX SE | Healthcare | 0.6% | $18.5m | 19,955 | 470% | added |
| 42 | NVCT NUVECTIS PHARMA INC | 0.6% | $18.4m | 1,000,000 | – | new | |
| 43 | CAPR CAPRICOR THERAPEUTICS INC | Healthcare | 0.6% | $18.3m | 761,737 | – | new |
| 44 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 0.6% | $18.3m | 450,889 | -69% | reduced |
| 45 | PRLD PRELUDE THERAPEUTICS INC | 0.6% | $18.0m | 3,378,378 | – | new | |
| 46 | XENE XENON PHARMACEUTICALS INC | Healthcare | 0.6% | $16.1m | 267,000 | -9% | reduced |
| 47 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.5% | $15.8m | 3,377,981 | -11% | reduced |
| 48 | KINIKSA PHARMACEUTICALS INTL | 0.5% | $15.8m | 246,353 | -53% | reduced | |
| 49 | KIDS ORTHOPEDIATRICS CORP | Healthcare | 0.5% | $14.0m | 732,144 | 19% | added |
| 50 | AVALYN PHARMACEUTICALS INC | 0.5% | $13.8m | 419,000 | – | new |
What did Soleus Capital Management, L.P. sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| PCVX VAXCYTE INC | 24.2% | $22.4m |
| ICLR ICON PLC | 23.0% | $21.2m |
| TVTX TRAVERE THERAPEUTICS INC | 17.5% | $16.2m |
| INBX INHIBRX BIOSCIENCES INC | 9.5% | $8.8m |
| DXCM DEXCOM INC | 9.5% | $8.8m |
| IMUX IMMUNIC INC | 5.4% | $5.0m |
| ETON ETON PHARMACEUTICALS INC | 4.4% | $4.1m |
| ARWR ARROWHEAD PHARMACEUTICALS IN | 1.9% | $1.8m |
| CTMX CYTOMX THERAPEUTICS INC. | 1.5% | $1.4m |
| COGT COGENT BIOSCIENCES INC | 0.4% | $384.9k |
| TYRA TYRA BIOSCIENCES INC | 0.4% | $383.0k |
| STAA STAAR SURGICAL CO | 0.4% | $374.0k |
| ANAB ANAPTYSBIO INC | 0.4% | $332.8k |
| RAPP RAPPORT THERAPEUTICS INC | 0.3% | $312.9k |
| ZYME ZYMEWORKS INC | 0.3% | $250.4k |
| LB PHARMACEUTICALS INC | 0.3% | $246.6k |
| ORKA ORUKA THERAPEUTICS INC | 0.3% | $245.2k |
| JSPR JASPER THERAPEUTICS INC | 0.3% | $242.1k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 88.3% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Soleus Capital Management, L.P.'s portfolio?
Across every quarter Soleus Capital Management, L.P. has filed, its median largest position is 12.0% of the book and its median top-ten weight is 49.6%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 17.0 completed holding spells, the median lasted 1.0 quarters; 97.0 positions are still open and their final length is unknown.